Convalescent plasma or hyperimmune immunoglobulin for people with COVID‐19: a living systematic review
Background Convalescent plasma and hyperimmune immunoglobulin may reduce mortality in patients with viral respiratory diseases, and are being investigated as potential therapies for coronavirus disease 2019 (COVID‐19). A thorough understanding of the current body of evidence regarding benefits and r...
| Principais autores: | , , , , , , , , , , , , , |
|---|---|
| Formato: | Journal article |
| Idioma: | English |
| Publicado em: |
Cochrane Collaboration
2021
|